Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings

Univar Solutions bags exclusive US & Canada deal for Ingredion Pharmaceutical starches

Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing

Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets

Lupin tops world pharma and all Indian sectors in S&P ESG rankings

Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally

Synthekine teams up with Merck to test breakthrough lung cancer combo

The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line

Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America

New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform